Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

KiTZ clinical trail unit

Our KiTZ Clinical Trial Unit (ZIPO) consists of a multidisciplinary team looking after young cancer patients for whom standard treatment procedures have not been successful. During clinical trials the team enables these children and adolescents to gain access to new treatment options under controlled conditions whenever possible. Further information you find here.

Molecular Diagnostics Studies

Today, most brain tumors in childhood and adolescence are in principle curable by combinations of surgery, chemotherapy and radiotherapy. About every fourth patient is still suffering from a relapse - a situation for which there are often no established treatment options. In order to find new treatment options for the affected patients, scientists of the preclinical program of the KiTZ analyse the tumor tissue using state-of-the-art methodologies for molecular target identification. Further information you find here.

Innovative Phase I/II Studies

Once children and adolescents suffer a disease relapse, despite first-line therapy and intensive pre-treatment, their chances of recovery are often limited ̶  especially in the case of solid tumors or brain tumors. Thanks to far-reaching developments in molecular genetic analysis and a large number of new so-called targeted drugs and immunotherapeutic approaches, we are confident to better help these children in the near future. Further unformation you find here.

to top
powered by webEdition CMS